Navigation Links
Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
Date:10/28/2009

CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.

Susceptibility of CEM-101 and more than 25 other antibiotics was tested against 1,737 multidrug-resistant S. pneumoniae strains collected in 2008 from medical centers in the U.S., Europe and Latin America. CEM-101 demonstrated 100% coverage (100% inhibition at less than or equal to 1 microgram/ml) against these strains. Activity was slightly better than telithromycin (MIC90 of 0.25 microgram/ml for both; range of less than or equal to 0.008 to 1 for CEM-101 vs. less than or equal to 0.06 to 2 for telithromycin) and at least four-fold better than linezolid (MIC90 of 1 microgram/ml) or vancomycin (MIC90 of less than or equal to 1 microgram/ml). The study will be presented during a poster session on October 30.

CEM-101 is a new fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, as well as non-bacterial pathogens such as Plasmodium falciparum. The compound recently completed a Phase 1 clinical trial and is in preparation for a Phase 2 trial in moderate to moderately-severe community-acquired bacterial pneumonia.

"The rise of multidrug-resistant organisms has become an increasing public health issue, particularly for vulnerable patient populations including those with challenging respiratory infections," said Prabhavathi Fernandes, Ph.D., Chief Executive Officer of Cempra Pharmaceuticals. "New medications are needed that are safe and effective against these difficult-to-treat pathogens. We believe that the growing database showing the potency and broad-spectrum activity of CEM-101, not only against the pneumococcal strains presented here, but agai
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
2. Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy, According to HealthCore Study Presented at ISPOR
3. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
4. The Most Advanced Solution for the Reduction of Stretch Marks Based on TriPollar(R) Technology Presented at the Upcoming EADV Congress
5. Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
6. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
7. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
8. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
9. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
10. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
11. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
(Date:10/31/2014)... , November 3, 2014 ... men with BPH to discuss "male orgasmic dysfunction" with ... ability to treat prostate symptoms while preserving sexual function ... welcomes the publication of a paper in the British ... from enlarged prostate to discuss with their doctors the ...
(Date:10/31/2014)... , Oct. 30, 2014 Migranade, Inc. announced ... be available to the 36 million U.S. migraine sufferers ... technology that targets the actual cause of migraines and ... pain and not the source Migranade is assured to ... MIGRANADE Migraine Relief is available at http://www.migranade.com ...
Breaking Medicine Technology:Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2Game Changing Migraine Medication To Be Available November 2014 2
... MYSTIC, Conn., Aug. 17 Amarin Corporation plc (Nasdaq: ... a focus on cardiovascular disease, today announced that Colin ... (CEO) and a member of the Company,s Board of ... responsible for driving forward the Company,s strategy to maximize ...
... - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ... care and gastroenterology markets, today announces financial results for the ... for full year 2010. Net Revenue:   ... was $10.7 million, up 9% from $9.8 million for the ...
Cached Medicine Technology:Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer 2Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer 3Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer 4Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 2Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 3Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 4Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 5Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 6Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 7Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 8Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 9Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 10Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 11Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 12Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 13
(Date:10/31/2014)... 31, 2014 Springboard Biodiesel, a ... small scale BioPro™ biodiesel processors, announced on Thursday ... improve the performance and efficiency of small-scale biodiesel ... trio will recover more than 99% of ... the glycerin by-product produced while making biodiesel. ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org reveals that the ... from Alzheimer's disease. , In fact, Alexander Lynch has ... His father pointed a gun and shot him during an ... of this method understood that he needed to do something ... is based on years of research. The author of the ...
(Date:10/31/2014)... At the start of 2014, numerous news ... monoxide poisoning in their homes. Now, as 2015 (and ... Missouri-based heating and cooling company is taking a more ... the home heating season with the assurance that their ... Nov. 1, 2014, E and Q Heating and Cooling ...
(Date:10/31/2014)... FRIDAY, Oct. 31, 2014 (HealthDay News) -- Surgery for ... on where in the United States you live, a ... will experience low back pain at some point in ... receive professional medical care for a spine problem," co-author ... & Clinical Practice, said in a college news release. ...
(Date:10/31/2014)... research suggests that insomnia is a major contributor to ... fatal injuries. The results underscore the importance of the ... Sleep Awareness Project. , Results show that the risk ... with the number of insomnia symptoms present. People with ... likely to die from a fatal injury than those ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... Crdentia Corp. (OTC Bulletin,Board: CRDT), a leading U.S. ... has been awarded an exclusive healthcare staffing,contract by ... Rock Raceway,is a new development project that includes ... single-family lots. High Rock Raceway has partnered ...
... the Campaign to Eliminate Drunk Driving, ST. LOUIS, ... -- a holiday that traditionally brings large numbers of ... supporters have,convened in St. Louis to kick off their ... and Suites Hotel 800 Washington Ave, St.,Louis, Mo. The ...
... reveals racial disparities, troublesome drug side effects , , THURSDAY, ... first annual Breast Cancer Symposium shed light on racial ... can affect survival, and how nagging side effects cause ... in San Francisco, is co-sponsored by the American Society ...
... First-year Results of Guiding Stars, ... System, SCARBOROUGH, Maine, Sept. 6 Consumer,selection of ... outpacing,selection of those that don,t in many aisles of ... faster -- according to data in the year,since the ...
... MYL ) today announced that Mylan Pharmaceuticals Inc. has ... for its,Abbreviated New Drug Application (ANDA) for Carvedilol Tablets, ... Carvedilol Tablets are the generic version of GlaxoSmithKline,s,Coreg(R) Tablets. ... the 12 months ending June 30, 2007, for the ...
... Sept. 5 Fairbank Farms, a national,ground beef ... Ground Round Beef Patties. The ground beef patties, ... purchased by consumers in New,England on Wednesday September ... an abundance of caution, the product has been ...
Cached Medicine News:Health News:Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services 2Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 2Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 3Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 4Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 5Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 6Health News:Studies Shed New Light on Breast Cancer, Treatment 2Health News:Studies Shed New Light on Breast Cancer, Treatment 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 2Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 4
...
...
...
EDM Lumbar Drainage Kit with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in the lumen....
Medicine Products: